E-viri
Recenzirano
-
Coles, Charlotte E; Earl, Helena; Anderson, Benjamin O; Barrios, Carlos H; Bienz, Maya; Bliss, Judith M; Cameron, David A; Cardoso, Fatima; Cui, Wanda; Francis, Prudence A; Jagsi, Reshma; Knaul, Felicia Marie; McIntosh, Stuart A; Phillips, Kelly-Anne; Radbruch, Lukas; Thompson, Mareike K; André, Fabrice; Abraham, Jean E; Bhattacharya, Indrani S; Franzoi, Maria Alice; Drewett, Lynsey; Fulton, Alexander; Kazmi, Farasat; Inbah Rajah, Dharrnesha; Mutebi, Miriam; Ng, Dianna; Ng, Szeyi; Olopade, Olufunmilayo I; Rosa, William E; Rubasingham, Jeffrey; Spence, Dingle; Stobart, Hilary; Vargas Enciso, Valentina; Vaz-Luis, Ines; Villarreal-Garza, Cynthia; Arreola-Ornelas, Hector; Bhadelia, Afsan; Boughey, Judy C; Chatterjee, Sanjoy; Dodwell, David; Doubova, Svetlana; Du Plooy, Dorothy; Essue, Beverley; Goel, Neha; Gralow, Julie; Hawley, Sarah; Kiely, Belinda; Mann, Ritse; Mertz, Shirley; Palmieri, Carlo; Poortmans, Philip; Spanic, Tanja; Stephen, Lesley; Symmans, Fraser; Towns, Catherine; Verhoeven, Didier; Vinnicombe, Sarah; Watkins, David; Yip, Cheng-Har; Zikmund-Fisher, Brian
The Lancet (British edition), 05/2024, Letnik: 403, Številka: 10439Journal Article
Over a 2-year period, we brainstormed ideas, scoped the literature, obtained funding for dedicated pilot research that provided new data, and produced this Commission report to reduce the effects that breast cancer has on society. Costs and suffering can be financial, physical, psychological, emotional, and social, they affect children, families, local communities, and wider society, can occur at all stages of breast cancer, and are evident even within health-care services that are free at the point of delivery. Equitable access to early diagnosis and treatment is a fundamental need for all individuals to improve their breast cancer survival and quality of life. In collaboration with the WHO Global Breast Cancer Initiative, we call for action to deliver stage-shifting, as a sustained decline in breast cancer mortality rates is achieved by diagnosing at least 60% of invasive cancers at stages I–II.
